Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Overview
Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.
Technology and Innovation
Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.
Product Portfolio and Market Position
The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.
Patient and Physician Support
An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.
Global Reach and Regulatory Milestones
Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.
Competitive Landscape and Differentiators
Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.
Conclusion
Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.
Nevro Corp. (NYSE: NVRO), a leader in medical devices aimed at chronic pain treatment, announced that its Chairman and CEO, D. Keith Grossman, will present at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 10:50 AM ET. A live webcast and archived recording will be accessible on Nevro's website. The company specializes in innovative spinal cord stimulation (SCS) systems, including the Senza® platform, delivering proprietary 10 kHz Therapy.
On August 25, 2021, Supermoon Capital launched a $36 million venture fund focused on early-stage startups innovating in the sleep sector. This fund is the first of its kind, targeting the growing 'Night Market™,' which is valued at $488 billion. Co-founded by Pat Connolly and Michael Masterson, the fund aims to address significant sleep issues affecting 75% of Americans. Investments include six startups, such as Clair Labs and Endel, aimed at improving sleep health through science-backed innovations.
Nevro Corp. (NYSE: NVRO), a leading medical device company, will be represented by Chairman, CEO, and President D. Keith Grossman at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 11:45 AM Eastern Time. Investors can access a live webcast and an archived recording of the presentation on Nevro's website. The company specializes in innovative solutions for chronic pain treatment, including its proprietary Senza spinal cord stimulation systems.
Nevro Corp. (NYSE: NVRO), a medical device leader in chronic pain solutions, announced that CEO D. Keith Grossman will present at the Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:00 am ET. A live webcast of the presentation will be available on Nevro's investor website. Nevro specializes in innovative spinal cord stimulation systems, including the Senza, Senza II, and Senza Omnia, delivering proprietary 10 kHz Therapy. Investors are encouraged to monitor the company's website for updates and important information.
Nevro Corp. (NVRO) reported Q2 2021 revenues of $102.3 million, an 81% increase from the previous year. Despite a net loss of $15.8 million, non-GAAP adjusted EBITDA improved to $3.0 million. The FDA approved its 10 kHz spinal cord stimulation therapy for painful diabetic neuropathy, enhancing its market position. However, Q3 revenue guidance is set at $90-$93 million, reflecting a decrease of 14%-17% year-over-year. The company is cautious due to ongoing COVID-19 impacts on patient procedures and future growth prospects.
Nevro Corp. (NYSE: NVRO) has received FDA approval for its Senza® System to treat Painful Diabetic Neuropathy (PDN) using 10 kHz spinal cord stimulation. This makes it the only FDA-approved spinal cord stimulation system specifically indicated for PDN. The company will launch this therapy in the U.S. under the HFX™ branding. Nevro anticipates a mid-single digit million revenue contribution from PDN in 2021, primarily in Q4, with higher revenue expected in future years. The company also announced preliminary Q2 2021 revenue of approximately $102.3 million.
Nevro Corp. (NYSE: NVRO) has announced it will report its Q2 2021 financial results on August 4, 2021, after market close. A conference call to discuss these results will take place at 1:30 pm PT / 4:30 pm ET on the same day. Interested investors can join by phone or via a live webcast on Nevro's website. The company focuses on innovative solutions for treating chronic pain, highlighted by its proprietary 10 kHz Therapy, which has shown efficacy in reducing opioid use in many patients.
Nevro Corp. (NYSE: NVRO) announced data from the SENZA Non-Surgical Refractory Back Pain (NSRBP) Randomized Controlled Trial (RCT) will be presented at the ASIPP annual meeting from June 24-26, 2021. The study compares Nevro's 10 kHz spinal cord stimulation (SCS) plus Conventional Medical Management to CMM alone in 159 patients. Previous 3-month results indicated superior pain relief for the 10 kHz SCS cohort. The 6-month results will be shared by Dr. Kapural on June 25, with plans to publish findings in a peer-reviewed journal and follow participants for 24 months. An investor briefing will also take place on June 25.
Nevro Corp. (NYSE: NVRO) announced data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial will be presented at the American Diabetes Association (ADA) 81st Scientific Sessions from June 25-29, 2021. The study compares Nevro's 10 kHz spinal cord stimulation (SCS) to conventional medical management in 216 patients. Initial results showed significant pain relief and improved quality of life. CEO D. Keith Grossman emphasized the potential for FDA approval and market expansion, aiming to address a $3.5 to $5 billion market for PDN treatment.
Nevro Corp. (NYSE: NVRO) announced it will host an analyst and investor briefing on June 25, 2021, during the American Diabetes Association's 81st Scientific Sessions. The event, led by Chairman and CEO D. Keith Grossman, will provide updates on the SENZA-PDN and SENZA-NSRBP clinical studies, along with a Q&A session. Participants can join via conference call or through a live audio webcast. For more details, visit Nevro's website. Nevro specializes in innovative solutions for chronic pain management, notably through its proprietary 10 kHz therapy.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
What is Nevro Corp's primary business?
Which products form the core of Nevro's portfolio?
How does Nevro's spinal cord stimulation system work?
In which markets are Nevro's products available?
What role does technology play in Nevro's treatments?
How does Nevro support its patients and healthcare providers?
What differentiates Nevro from other pain management companies?
What conditions do Nevro's therapies target?
